CJC-1295 vs Ipamorelin: Comparing Two Growth Hormone Secretagogues in Research
CJC-1295 vs Ipamorelin: Comparing Two Growth Hormone Secretagogues in Research
CJC-1295 and Ipamorelin are two of the most studied growth hormone (GH) secretagogues in peptide research. Despite their shared endpoint — stimulation of endogenous growth hormone release — they operate through entirely different receptor systems, have different pharmacokinetic profiles, and produce distinct patterns of GH secretion. This article compares the published research on both compounds.
For individual compound overviews, see our deep-dives on CJC-1295 and Ipamorelin.
Receptor Pathways: GHRH vs GHS
The most fundamental difference between CJC-1295 and Ipamorelin is the receptor each targets.
CJC-1295 → GHRH Receptor
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It acts as an agonist at the GHRH receptor (GHRHR), a G protein-coupled receptor on somatotroph cells in the anterior pituitary. Binding triggers the Gs/adenylyl cyclase/cAMP/PKA cascade, stimulating GH gene transcription, synthesis, and secretion.
CJC-1295 was developed by modifying the first 29 amino acids of human GHRH with four amino acid substitutions to resist degradation by DPP-IV. It exists in two forms:
- Without DAC (Mod GRF 1-29): Half-life ~30 minutes, produces pulsatile GH release
- With DAC (Drug Affinity Complex): Half-life ~6–8 days due to albumin binding, produces sustained GH elevation
(Jetté et al., Endocrinology, 2005; PMID: 15845616; Teichman et al., JCEM, 2006; PMID: 16368745)
Ipamorelin → GHS Receptor (Ghrelin Receptor)
Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. This is the same receptor activated by endogenous ghrelin, but Ipamorelin's selectivity profile is distinct from both ghrelin and earlier GHS-R agonists like GHRP-6.
In preclinical studies, Ipamorelin demonstrated potent GH release with minimal effects on ACTH, cortisol, and prolactin — making it one of the most selective GHS-R agonists characterized in the literature (Raun et al., European Journal of Endocrinology, 1998; PMID: 9916872).
Why Two Pathways Matter
The GHRH and GHS receptor pathways converge on the somatotroph cell but through different intracellular signaling cascades. GHRH receptor activation works primarily through cAMP/PKA, while GHS receptor activation involves phospholipase C, IP3, and intracellular calcium mobilization. These distinct signaling mechanisms are the basis for the synergistic GH release observed when both pathways are activated simultaneously in preclinical models.
Pharmacokinetic Comparison
| Parameter | CJC-1295 (no DAC) | CJC-1295 (with DAC) | Ipamorelin |
|---|---|---|---|
| Receptor | GHRHR | GHRHR | GHS-R1a (ghrelin receptor) |
| Length | 30 amino acids | 30 amino acids + DAC linker | 5 amino acids |
| Half-life | ~30 minutes | ~6–8 days | ~2 hours |
| GH release pattern | Pulsatile | Sustained elevation | Pulsatile |
| Selectivity | GHRH-specific | GHRH-specific | GHS-R selective (minimal ACTH/cortisol) |
| Feedback preservation | Subject to somatostatin inhibition | Partially overrides pulsatility | Subject to somatostatin inhibition |
Synergistic Research
One of the most significant findings in GH secretagogue research is the synergistic effect observed when GHRH-pathway and GHS-pathway compounds are co-administered.
In preclinical models, combining a GHRH analog (such as CJC-1295 without DAC) with a GHS receptor agonist (such as Ipamorelin) produced GH release that exceeded the sum of either compound administered alone. This synergy arises because the two pathways use different intracellular signaling mechanisms that converge on the GH secretory machinery of the somatotroph cell.
The practical implication for research: co-administration allows investigation of robust GH axis stimulation through physiological pathways, in contrast to direct exogenous GH administration which bypasses the pituitary entirely.
CALM Peptides offers a 2X Blend (CJC-1295 without DAC / Ipamorelin) for researchers studying this combination. Individual compounds are also available: CJC-1295 without DAC, CJC-1295 with DAC, and Ipamorelin.
Browse all strength peptides or explore our full catalog.
Selectivity Profiles
A key differentiator for Ipamorelin is its selectivity. Earlier GHS-R agonists like GHRP-6 and GHRP-2 were associated with significant increases in cortisol, ACTH, and prolactin in addition to GH. Ipamorelin, in contrast, was shown to stimulate GH release at concentrations that produced minimal changes in these other hormones (Raun et al., European Journal of Endocrinology, 1998; PMID: 9916872).
CJC-1295 is inherently selective for the GHRH receptor, so off-target hormone stimulation is not a primary concern. However, the with-DAC form's sustained GH elevation may have different implications for IGF-1 axis dynamics compared to the pulsatile pattern produced by the without-DAC form.
Frequently Asked Questions
What is the main difference between CJC-1295 and Ipamorelin?
They target different receptors. CJC-1295 activates the GHRH receptor, while Ipamorelin activates the GHS receptor (ghrelin receptor). Both stimulate growth hormone release but through distinct intracellular signaling pathways.
Why are CJC-1295 and Ipamorelin often studied together?
Because their receptor pathways use different signaling mechanisms (cAMP/PKA for GHRH vs PLC/IP3/calcium for GHS-R), co-administration has been observed to produce synergistic GH release — a combined response greater than the sum of individual responses.
Which form of CJC-1295 is typically combined with Ipamorelin?
CJC-1295 without DAC (Mod GRF 1-29) is typically paired with Ipamorelin in research settings, as both produce pulsatile GH release that preserves physiological secretion patterns and somatostatin feedback.
How does Ipamorelin's selectivity compare to other GHS-R agonists?
Ipamorelin is among the most selective GHS-R agonists characterized in preclinical research. Unlike GHRP-6 and GHRP-2, Ipamorelin produced minimal effects on ACTH, cortisol, and prolactin at GH-stimulatory concentrations.
The information presented in this article is for educational and informational purposes only and is not intended as medical advice. CJC-1295 and Ipamorelin are sold as research chemicals for laboratory use only. They are not intended for human consumption, and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.
For research use only. Not for human consumption.
The information presented in this article is for educational and informational purposes only and is not intended as medical advice. All products referenced are sold as research chemicals for laboratory use only. They are not intended for human consumption and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.